7Fonteyn M,Bauer W S.Using qualitative evaluation in a feasibility study to improve and refine a complementary therapy intervention prior to subsequent research[J].Complement Ther Clin Pract,2005,11:247-252.
5Webster KA,Discher DJ,Bishopric NH.Induction and nuclearaccumulation of fos and jun proto-oncogenes in hypoxic cardiacmyocytes[J].J Biol Chem,1993,268(22):16852-16858.
6Pi Y,Goldenthal MJ,Marin-Garcia J.Mitochondrial involvement inIGF-1 induced protection of cardiomyocytes against hypoxia/reoxygenation injury[J].Mol Cell Biochem,2007,301(1-2):181-189.
7Gomez L A,Alekseev AE,Aleksandrova LA,et al.Use of the MTTassay in adult ventricular cardiomyocytes to assess viability:effects ofadenosine and potassium on cellular survival[J].J Mol Cell Cardiol,1997,29(4):1255-1266.
8Mu YL,Xie YY,Zhou L,et al.Cardioprotective effect ofmethylamine in isolidone,a new compound,in hypoxia/reoxygenationinjury in cultured rat cardiac myocytes[J].Chem Biodivers,2009,6(8):1170-1177.
9Elizabeth D,DanzB,Skramsted J,et al.Resveratrol preventsdoxorubicin cardiotoxicity through mitochondrial stabilization and theSirt1 pathway[J].Free Radical Biology and Medicine,2009,46(12):1589-1597.
10Kerr ME,Bender CM,Monti EJ.An introduction to oxygen freeradicals[J].Heart Lung,1996,25(3):200-209.
